AI drug discovery is not an ideal market -- crowded, and long horizons to validation checkpoints. Our value prop to pharma is in clinical trials utilities. Rela

AI drug discovery is not an ideal market -- crowded, and long horizons to validation checkpoints. Our value prop to pharma is in clinical trials utilities. Relative to drug discovery, better path from pilots to revenue deals, but still cumbersome. Nonetheless your advice to target startups is sound :)